Bernstein upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $385.00 (from $436.00).

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $300.03 yesterday.